Gedeon Richter Strikes $16.5m Global Tocilizumab Deal
Agreement For Biosimilar To Actemra/RoActemra Reached With Taiwan’s Mycenax
Gedeon Richter has struck a deal worth $16.5m with Taiwan’s Mycenax for global rights to a tocilizumab biosimilar version of Actemra/RoActemra, setting a date for planned launches in the EU, Japan, Canada and Australia.
You may also be interested in...
Dr Reddy’s has notched up another achievement for its biosimilar tocilizumab candidate, after the intravenous presentation of the firm’s proposed Actemra/RoActemra rival completed a Phase I study.
Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.
Fresenius Kabi has been tipped to strike first in the race to launch a biosimilar to Actemra – a market where competition “is likely to be thin for some time.”